Epidermal growth factor enhances MPC-83 pancreatic cancer cell migration through the upregulation of aquaporin 3

Molecular Medicine Reports

Volumn 6, Issue 3, 2012, Pages 607-610

  Liu, Weijun ^a   Wang, Kunhua ^a   Gong, Kunmei ^a   Li, Xiaogang ^a   Luo, Kaiyuan ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Aquaporin 3; Cell migration; Epidermal growth factor receptor; Pancreatic cancer cell

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; AQUAPORIN 3; COPPER SULFATE; EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CELL ACTIVATION; CELL MIGRATION; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; AQUAPORIN 3; BUTADIENES; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; NITRILES; PANCREATIC NEOPLASMS; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; UP-REGULATION;

EID: 84865191799     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.966     Document Type: Article

References (12)

1. Jeyaseelan K, Sepramaniam S, Armugam A, et al: Aquaporins: a promising target for drug development. Expert Opin Ther Targets 10: 889-909, 2006. (Pubitemid 44816751)
2. Walz T, Fujiyoshi Y and Engel A: The AQP structure and functional implications. Handb Exp Pharmacol: 31-56, 2009.
3. Verkman AS, Hara-Chikuma M and Papadopoulos MC: Aquaporins-new players in cancer biology. J Mol Med (Berl) 86: 523-529, 2008.
4. Sartore-Bianchi A, Bencardino K, Di Nicolantonio F, et al: Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Target Oncol 5: 19-28, 2010.
5. Perol M and Arpin D: Tyrosine kinase inhibitors in the management of non-small cell lung cancer. Rev Mal Respir 24: 6S188-6S197, 2007.
6. Valentini AM, Pirrelli M and Caruso ML: EGFR-targeted therapy in colorectal cancer: does immunohistochemistry deserve a role in predicting the response to cetuximab? Curr Opin Mol Ther 10: 124-131, 2008. (Pubitemid 351498874)
7. Nico B and Ribatti D: Role of aquaporins in cell migration and edema formation in human brain tumors. Exp Cell Res 317: 2391-2396, 2011.
8. Papadopoulos MC, Saadoun S and Verkman AS: Aquaporins and cell migration. Pflugers Arch 456: 693-700, 2008. (Pubitemid 351692135)
9. Giaccone G and Wang Y: Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat Rev 37: 456-464, 2011.
10. Mahipal A, McDonald MJ, Witkiewicz A, et al: Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma. Med Oncol 29: 134-139.
11. Steelman LS, Franklin RA, Abrams SL, et al: Roles of the Ras/ Raf/MEK/ERK pathway in leukemia therapy. Leukemia 25: 1080-1094, 2011.
12. Dragovich T and Campen C: Anti-EGFR-targeted therapy for esophageal and gastric cancers: an evolving concept. J Oncol: 804108, 2009.